Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 373

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 16I
Chunk 373
---
         3.21         ( 3.32)  
  Net profit/loss (-) attributable to owners of the parent (Euro, in thousands)                 €                            74,082      211,697      ( 217,991)  
  Number of shares (thousands)                                                                                                                                    
  Weighted average number of shares for the purpose of diluted earnings/loss (-) per share                                   65,897       65,884          65,699  
  Number of dilutive potential ordinary shares                                                                                   45           49               —  
  Diluted earnings/loss (-) per share (Euros)                                                   €                              1.12         3.21         ( 3.32)  

As our operations reported a net loss in 2022, the outstanding subscription rights (specified in note32) have an anti-dilutive effect rather than a dilutive effect. Consequently, basic and diluted loss per share were the same for 2022.

Reference is also made to note 2 where an explanation is provided about the terms and conditions of the outstanding subsequent Warrant B that can, potentially, be exercised by Gilead and lead to a dilutive effect. Due to the exercise price mechanism of the Gilead Warrant B, this warrant was out-of-the-money for all years presented.

13. Goodwill and impairment of goodwill

  On January 1, 2023                    69,813  
  Exchange differences on goodwill      ( 256)  
  On December 31, 2023                  69,557  
  Exchange differences on goodwill         453  
  On December 31, 2024                  70,010  

The goodwill resulting from both the acquisition of CellPoint (€62.4million) and AboundBio (€7.6million) was allocated to the same cash-generating unit (CGU), “ CAR-T/Cell therapy” (which was the same as “oncology” before). The intangible assets acquired as a result of both business combinations were also allocated to this cash-generating unit, together with some other (in)tangible assets related to the “ CAR-T/Cell therapy” cash-generating unit. The valuation method of the recoverable amount of this cash-generating unit is based on the fair value less costs of disposal.

The valuation technique that was applied to determine the fair value less costs of disposal of the cash-generating unit is a discounted cash flow method (“ DCF”) with projected cash